芬兰人和拉普人中异喹胍羟基化的多态性。
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
作者信息
Arvela P, Kirjarinta M, Kirjarinta M, Kärki N, Pelkonen O
机构信息
Department of Pharmacology, University of Oulu, Finland.
出版信息
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
Abstract
Debrisoquine hydroxylation polymorphism was studied in 155 Finns and 70 Lapps. The frequency of the poor metabolizer phenotype was 3.2% among Finns (95% confidence interval 0.4-6.0%) and 8.6% among Lapps (95% confidence interval 2.0-15.1%).
摘要
对155名芬兰人和70名拉普人进行了异喹胍羟基化多态性研究。在芬兰人中，代谢不良者表型的频率为3.2%（95%置信区间0.4 - 6.0%），在拉普人中为8.6%（95%置信区间2.0 - 15.1%）。
相似文献
1
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
2
Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
Zhongguo Yao Li Xue Bao. 1990 Jan;11(1):7-10.
3
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
4
Diurnal effects on debrisoquine hydroxylation phenotyping.
Eur J Clin Pharmacol. 1988;35(4):441-2. doi: 10.1007/BF00561381.
5
Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
Hum Toxicol. 1988 May;7(3):273-6. doi: 10.1177/096032718800700308.
6
Debrisoquine hydroxylation phenotyping: do we expect too much?
Lancet. 1990 Sep 15;336(8716):694. doi: 10.1016/0140-6736(90)92193-l.
7
Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Pharmacol Toxicol. 1993 Feb;72(2):113-5. doi: 10.1111/j.1600-0773.1993.tb00300.x.
8
Methoxyphenamine and dextromethorphan as safe probes for debrisoquine hydroxylation polymorphism.
Lancet. 1984 Dec 15;2(8416):1393. doi: 10.1016/s0140-6736(84)92081-6.
9
Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
Clin Pharmacol Ther. 1979 Nov;26(5):584-91. doi: 10.1002/cpt1979265584.
10
Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.
Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.
引用本文的文献
1
Polymorphism in CYP1A1 and CYP2D6 genes: possible association with susceptibility to lung cancer.
Environ Health Perspect. 1993 Oct;101 Suppl 3(Suppl 3):109-12. doi: 10.1289/ehp.93101s3109.
2
Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.
Eur J Clin Pharmacol. 1990;39(6):533-7. doi: 10.1007/BF00316090.
3
The effects of diltiazem on hepatic drug metabolizing enzymes in man using antipyrine, trimethadione and debrisoquine as model substrates.
Br J Clin Pharmacol. 1991 Mar;31(3):353-5. doi: 10.1111/j.1365-2125.1991.tb05543.x.
4
Debrisoquine oxidation polymorphism in a Tasmanian population.
Eur J Clin Pharmacol. 1991;40(5):529-32. doi: 10.1007/BF00315235.
本文引用的文献
1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7.
3
The Upjohn Award Lecture 1981/La Conférence Upjohn 1981. The metabolism of xenobiotics in different populations.
Can J Physiol Pharmacol. 1982 Jan;60(1):1-12. doi: 10.1139/y82-001.
4
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.
J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321.
5
The genetic control of drug oxidation in the liver.
Int J Clin Pharmacol Res. 1983;3(6):421-5.
6
Demography of the Skolt Lapps in Northern Finland.
Suom Hammaslaak Toim. 1971;67:Suppl 1:24-38.
7
Isoniazid inactivation in Finns and Lapps as demonstrated by various methods.
Am Rev Respir Dis. 1973 Aug;108(2):375-8. doi: 10.1164/arrd.1973.108.2.375.
8
Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Clin Pharmacol Ther. 1985 Oct;38(4):402-8. doi: 10.1038/clpt.1985.194.
9
A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.
Clin Pharmacol Ther. 1985 Oct;38(4):394-401. doi: 10.1038/clpt.1985.193.
10
Confidence intervals rather than P values: estimation rather than hypothesis testing.
Br Med J (Clin Res Ed). 1986 Mar 15;292(6522):746-50. doi: 10.1136/bmj.292.6522.746.
Zotero 插件